860421acb1f0fde0…

{
  "id": "NCT00100282",
  "type": "Study",
  "data": {
    "briefSummary": "This is a multi-center, double-blind, inpatient study followed by outpatient, placebo-controlled, single-dose, dose-escalation evaluation of the safety and tolerability of PPI-1019 in patients with mild-moderate Alzheimer's disease (AD). Up to 12 sequential cohorts of 8 patients (6 active and 2 placebo) will be given a single PPI-1019 dose intravenously (IV) over 1 minute in order to determine a maximum tolerated dose (MTD). The MTD will be the dose immediately below the not-tolerated dose.",
    "completionDate": "2005-06",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "enrollmentCount": 125,
    "enrollmentType": null,
    "nctId": "NCT00100282",
    "phase": "PHASE1",
    "sponsorId": "praecis-pharmaceuticals-inc",
    "startDate": "2003-05",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease",
    "url": "https://clinicaltrials.gov/study/NCT00100282"
  }
}